HC Wainwright Has Negative Estimate for LBRX Q3 Earnings

LB Pharmaceuticals Inc (NASDAQ:LBRX) – Investment analysts at HC Wainwright dropped their Q3 2026 EPS estimates for LB Pharmaceuticals in a research note issued to investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.52) for the quarter, down from their previous estimate of ($0.95). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($4.67) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.49) EPS, FY2026 earnings at ($5.47) EPS, Q1 2027 earnings at ($1.55) EPS, Q2 2027 earnings at ($1.34) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.31) EPS and FY2027 earnings at ($5.48) EPS.

LBRX has been the topic of several other research reports. Piper Sandler restated an “overweight” rating and set a $78.00 price target on shares of LB Pharmaceuticals in a report on Monday, August 3rd. Weiss Ratings cut shares of LB Pharmaceuticals from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Stifel Nicolaus set a $53.00 price objective on shares of LB Pharmaceuticals in a research report on Thursday, August 13th. Roth Capital reissued a “buy” rating and issued a $37.00 target price on shares of LB Pharmaceuticals in a report on Sunday, May 17th. Finally, Wolfe Research initiated coverage on LB Pharmaceuticals in a research note on Tuesday, July 7th. They issued an “outperform” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.62.

LB Pharmaceuticals Trading Up 1.2%

LB Pharmaceuticals stock opened at $48.80 on Wednesday. The firm has a market capitalization of $1.57 billion and a P/E ratio of -14.19. LB Pharmaceuticals has a twelve month low of $13.36 and a twelve month high of $50.16. The stock’s fifty day simple moving average is $37.73 and its 200-day simple moving average is $30.71.

LB Pharmaceuticals (NASDAQ:LBRX) last announced its earnings results on Tuesday, August 11th. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.87).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new stake in shares of LB Pharmaceuticals during the fourth quarter worth $26,000. Bank of America Corp DE purchased a new position in LB Pharmaceuticals in the third quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in shares of LB Pharmaceuticals during the 4th quarter worth $34,000. Strs Ohio acquired a new position in shares of LB Pharmaceuticals during the 4th quarter worth $76,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of LB Pharmaceuticals in the 4th quarter valued at about $91,000.

LB Pharmaceuticals News Roundup

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target for LB Pharmaceuticals to $60 from $45 and maintained a “Buy” rating. The new target implies additional upside from the recent share price and likely provides the main positive catalyst for LBRX.
• Neutral Sentiment: HC Wainwright’s estimates indicate that LB Pharmaceuticals is still expected to report losses across upcoming quarters, including projected EPS of ($1.52) in Q3 2026, ($1.49) in Q4 2026, ($1.55) in Q1 2027, ($1.34) in Q2 2027, ($1.28) in Q3 2027 and ($1.31) in Q4 2027.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to ($5.47) from ($3.51) and its FY2027 forecast to ($5.48) from ($4.87). The firm also lowered several quarterly estimates, most notably Q3 2026 to ($1.52) from ($0.95), Q4 2026 to ($1.49) from ($1.07), and Q1 2027 to ($1.55) from ($1.13). These revisions signal expectations for deeper losses than previously projected.
• Negative Sentiment: LB Pharmaceuticals previously reported quarterly EPS of ($1.71), missing the consensus estimate of ($0.84) by $0.87. The company is not yet profitable, with analysts forecasting a current-year loss of approximately $4.67 per share.
• Neutral Sentiment: The reported August short-interest data showed zero shares sold short and a zero-day days-to-cover ratio, offering no meaningful indication of short-covering activity or bearish positioning.

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.